Literature DB >> 31211326

Missing Information on Sample Size.

.   

Abstract

Year:  2019        PMID： 31211326      PMCID： PMC6582259          DOI： 10.1001/jama.2019.6706

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  1 in total

1.  Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen).

Authors:  Roni Bitterman; Fidi Koppel; Cristina Mussini; Yuval Geffen; Michal Chowers; Galia Rahav; Lior Nesher; Ronen Ben-Ami; Adi Turjeman; Maayan Huberman Samuel; Matthew P Cheng; Todd C Lee; Leonard Leibovici; Dafna Yahav; Mical Paul
Journal:  BMJ Open       Date:  2021-02-08       Impact factor: 2.692
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.